Sinew Pharma Company Description

Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases.

The company’s products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630, a pre-clinical drug for treating patients with non-alcoholic steatohepatitis.

It is also developing SNP-810 for use in analgesic and antipyretic indications; and SNP-830 and SNP-840, which are used as hepatotoxicity-free analgesic medicines in the United States.

The company was founded in 2014 and is based in Taipei City, Taiwan.

Sinew Pharma Inc.

Country	Taiwan
Founded	2014
Industry	Biotechnology
Sector	Healthcare
Employees	52
CEO	Kai-Min Chu

Contact Details

Address: C516, Building C Taipei, 11571 Taiwan
Phone	886 2 2788 5365
Website	sinewpharma.com

Stock Details

Ticker Symbol	6634
Exchange	Taipei Exchange
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	TW0006634009
SIC Code	2834

Key Executives

Name	Position
Kai-Min Chu	Chief Executive Officer
Tzu-Wen Chen	Chief Financial Officer